RECORD // Company

Opus Genetics, Inc.

Formerly: Ocuphire Pharma, Inc.; REXAHN PHARMACEUTICALS, INC.; CORPORATE ROAD SHOW DOT COM INC; FERRARO FRANK

Built 2026-11-22T00:18:14Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • OPUS GENETICS, INC. · legal entity in this company's GLEIF ownership tree (LEI 529900C85NBMQFSETD92)
SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Opus Genetics, Inc · Ctgov · same registered legal name as 'Opus Genetics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

9 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001628280-26-072697

ItemValuePeriodFormFiledAccessionReport
Revenue$1,137,0003 months ended 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Net income (loss)$-46,495,0003 months ended 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Interest expense$222,0009 months ended 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Cash and cash equivalents$88,974,000at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Debt due in the next 12 months$0at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Debt due in year 2$0at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Debt due in year 3$0at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Debt due in year 4$0at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error
Debt due in year 5$0at 2026-09-3010-Q2026-11-100001628280-26-0726972026-11-22 00:18 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001228627
Ticker
IRD
EIN
113516358
CUSIP
67577R102
Record ID
sx:sec:0001228627

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Business address8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 277132026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:18 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$14,196,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:18 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-49,591,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:18 UTCReport an error
Total assets (at 2025-12-31)$50,243,0002025-12-3110-K, XBRL Assets2026-11-22 00:18 UTCReport an error
Stockholders' equity (at 2025-12-31)$15,348,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:18 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$45,091,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:18 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-35,253,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:18 UTCReport an error
Long-term debt (at 2025-12-31)$1,129,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-22 00:18 UTCReport an error
Form D total offering amount (D filed 2024-11-07)$25,778,6412024-11-07D2026-11-22 00:18 UTCReport an error
Form D total amount sold (D filed 2024-11-07)$25,778,6412024-11-07D2026-11-22 00:18 UTCReport an error
Form D industry groupBiotechnology2024-11-07D2026-11-22 00:18 UTCReport an error
Form D revenue rangeDecline to Disclose2024-11-07D2026-11-22 00:18 UTCReport an error
Form D date of first sale2024-10-222024-11-07D2026-11-22 00:18 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-10)On November 10, 2026 , Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before…2026-11-10SEC EDGAR 8-K 0001628280-26-072493 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 5.02 (filed 2026-10-21)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”). Effective on the Separation Date, the Company entered into a separation and release agreement with Dr. Jayagopal, which includes a consulting agreement (together, the “Letter Agreement”), which provides for a six-month consulting arrangement pursuant to which Dr. Jayagopal will provide transition services to the…2026-10-21SEC EDGAR 8-K 0001140361-26-040377 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 7.01 (filed 2026-10-15)Regulation FD Disclosure. On October 15, 2026, Opus Genetics, Inc. (the “Company”) issued a press release regarding the Company’s October 14, 2026 presentations at the Retina in Rio 2026 conference held in Rio de Janeiro, Brazil. The presentations covered clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 (the “OPGx-BEST1 Presentation”) and clinical data from the Company’s ongoing Phase 1/2/3 clinical trial of OPGx-LCA5 (the “OPGx-LCA5 Presentation”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the OPGx-BEST1 Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. A copy…2026-10-15SEC EDGAR 8-K 0001140361-26-039781 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
8-K Item 7.01 (filed 2026-09-11)Regulation FD Disclosure. On September 11, 2026, Opus Genetics, Inc. (the “Company”) issued a revised version of the Company’s data presentation, which was initially used in connection with its investor conference on September 9, 2026, announcing clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases. The original data presentation was furnished by the Company on a Current Report on Form 8-K on September 9, 2026. The revised version of the data presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, corrects an immaterial error in the translation of logMAR visual acuity into…2026-09-11SEC EDGAR 8-K 0001140361-26-036277 (text as filed, excerpt)2026-11-22 00:18 UTCReport an error
Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC$25,164,3702026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #2 (13F as filed): Caligan Partners LP$24,976,8152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #3 (13F as filed): ADAGE CAPITAL PARTNERS GP, L.L.C.$24,782,3752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #4 (13F as filed): BIOS Capital Management, LP$15,138,8932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$12,808,7622026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #6 (13F as filed): Balyasny Asset Management L.P.$12,691,1292026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$12,160,1872026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #8 (13F as filed): Boxer Capital Management, LLC$11,569,6502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #9 (13F as filed): Trails Edge Capital Partners, LP$11,276,4342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error
Largest institutional holder #10 (13F as filed): MILLENNIUM MANAGEMENT LLC$9,461,6352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:18 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.